This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2011
  • /
  • 11
  • /
  • Nomac/E2 is rejected by FDA as a contraceptive
Drug news

Nomac/E2 is rejected by FDA as a contraceptive

Read time: 1 mins
Last updated:10th Nov 2011
Published:10th Nov 2011
Source: Pharmawand
Zoely/Nomac/E2 is a combined contraceptive pill (nomegestrol acetate (a progestogen) and estradiol (an oestrogen) which was approved by EMA for Teva Pharma on 17 July 2011 to be launched by year end and rejected by the FDA for Merck Inc. some days ago.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.